|Positive WB detected in||SH-SY5Y cells|
|Western Blot (WB)||WB : 1:200-1:1000|
|Sample-dependent, check data in validation data gallery|
60123-1-Ig targets CXCL16 in WB, IHC, IF, ELISA applications and shows reactivity with human, mouse samples.
|Tested Reactivity||human, mouse|
|Cited Reactivity||human, mouse, rat|
|Host / Isotype||Mouse / IgG2a|
|Immunogen||CXCL16 fusion protein Ag4883|
|Full Name||chemokine (C-X-C motif) ligand 16|
|Calculated molecular weight||273 aa, 30 kDa|
|Observed molecular weight||35 kDa, 60 kDa|
|GenBank accession number||BC017588|
|Gene ID (NCBI)||58191|
|Purification Method||Caprylic acid/ammonium sulfate precipitation|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.|
CXCL16 is a recently discovered cytokine belonging to the CXC chemokine family, which is synthesised in plasmacytoid dendritic cell as a transmembrane molecule. It exists in a transmembrane and soluble form. The transmembrane form of CXCL16 functions as an adhesion molecule for CXCR6-expressing cells, whereas the soluble form of CXCL16 mediates infiltration of circulating cells into sites of injury. CXCL16, has been proposed as an important pathogenic mediator in inflammatory diseases, including rheumatoid arthritis, glomerulonephritis, or prostate cancer. CXCL16 has been implicated in some forms of renal disease such as lupus nephritis and antiglomerular basement membrane nephritis. CXCL16 also plays a pivotal role in the pathogenesis of angiotensin II-induced renal injury and fibrosis through regulation of macrophage and T cell infiltration and bone marrow-derived fibroblast accumulation.
Cancer Commun (Lond)
Activation of Piezo1 contributes to matrix stiffness-induced angiogenesis in hepatocellular carcinoma
Pathogenic Tconvs promote inflammatory macrophage polarization through GM-CSF and exacerbate abdominal aortic aneurysm formation.
Mol Med Rep
oxLDL promotes podocyte migration by regulating CXCL16, ADAM10 and ACTN4.
Klotho inhibits renal ox-LDL deposition via IGF-1R/RAC1/OLR1 signaling to ameliorate podocyte injury in diabetic kidney disease